- Immunic plans to use the money raised to support its clinical studies, day-to-day operations, and other general business needs.
- The company said that it is preparing to shift from a development-focused biotech into a commercial-stage company.
- Immunic looks to prioritize its Phase 3 ENSURE studies evaluating vidofludimus calcium in relapsing multiple sclerosis, with top-line results anticipated by year-end 2026.
Immunic Inc. (IMUX) announced on Friday that it has secured a private placement that could generate up to $400 million in gross proceeds, providing funding to advance its multiple sclerosis programs and support future product launches.
The financing, led by existing investor BVF Partners and including several institutional backers, includes $200 million in upfront proceeds and the potential for an additional $200 million if warrants are exercised.
The transaction is expected to close around February 17, pending customary conditions.
Financing To Advance Clinical Studies
Immunic plans to use the money raised to support its clinical studies, day-to-day operations, and other general business needs. Together with its existing cash and investments, the funds are expected to cover operating and capital costs through the end of 2027.
The company said that it is preparing to shift from a development-focused biotech into a commercial-stage company.
Following the announcement, Immunic stock traded over 33% higher in Friday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.
Multiple Sclerosis Programs Take Priority
Immunic plans complete its Phase 3 ENSURE studies evaluating vidofludimus calcium in relapsing multiple sclerosis, with top-line results anticipated by year-end 2026. The company aims to file a New Drug Application in mid-2027 and, if approved, launch in 2028. It also intends to initiate a Phase 3 program in primary progressive multiple sclerosis later this year, a trial projected to run up to four years.
“The proceeds from the initial closing are expected to provide sufficient runway through submission of an NDA in the United States in mid-2027 and to start preparations for the potential launch of vidofludimus calcium in RMS, as well as initiation of a phase 3 clinical program in PPMS.”
-Daniel Vitt, CEO, Immunic
Vitt will begin a search for a CEO to lead the next phase of growth. Vitt plans to transition into a senior strategic role while remaining on the board.
IMUX stock has declined by 9% in the last 12 months.
Also See: AAP Stock Surges 9% Pre-Market – What’s Fueling the Rally?
For updates and corrections, email newsroom[at]stocktwits[dot]com.